![Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4 - Basu - 2011 - The Prostate - Wiley Online Library Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4 - Basu - 2011 - The Prostate - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/53aba222-2b89-4145-aa2a-0757242aec75/mfig001.jpg)
Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4 - Basu - 2011 - The Prostate - Wiley Online Library
![PDF) Thioredoxins, Glutaredoxins, and Peroxiredoxins-Molecular Mechanisms and Health Significance: From Cofactors to Antioxidants to Redox Signaling PDF) Thioredoxins, Glutaredoxins, and Peroxiredoxins-Molecular Mechanisms and Health Significance: From Cofactors to Antioxidants to Redox Signaling](https://i1.rgstatic.net/publication/235518989_Thioredoxins_Glutaredoxins_and_Peroxiredoxins-Molecular_Mechanisms_and_Health_Significance_From_Cofactors_to_Antioxidants_to_Redox_Signaling/links/00b7d5140344bca690000000/largepreview.png)
PDF) Thioredoxins, Glutaredoxins, and Peroxiredoxins-Molecular Mechanisms and Health Significance: From Cofactors to Antioxidants to Redox Signaling
![Comparative analyses of copigmentation of cyanidin 3-glucoside and cyanidin 3-sophoroside from red raspberry fruits | Request PDF Comparative analyses of copigmentation of cyanidin 3-glucoside and cyanidin 3-sophoroside from red raspberry fruits | Request PDF](https://www.researchgate.net/images/template/default_publication_preview_large.png)
Comparative analyses of copigmentation of cyanidin 3-glucoside and cyanidin 3-sophoroside from red raspberry fruits | Request PDF
![Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial - The Lancet Oncology Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/181b8f53-cdd0-40c7-8448-278ba57ae889/gr3.jpg)